Cybersecurity

Trump acolyte, leftist icon: Who will be Colombia's next leader?

29 sec read7 views0 listens

Abelardo de la Espriella and Ivan Cepeda have advanced to the runoff for Colombia's presidency, representing extreme right-wing and leftist ideologies respectively. De la Espriella advocates a hardline approach against drug cartels with military support from the US and Israel, while Cepeda is a survivor of political violence who championed peace negotiations with FARC rebels. This election will determine the direction of Colombia’s policies on crime, human rights, and international relations.

Read the full article at Digital Journal

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

STAT+: Pharmalittle: We're reading about a Supreme Court setback for pharma, TrumpRx expands and much more

The U.S. Supreme Court declined to hear appeals from several pharmaceutical companies challenging Medicare's drug price negotiation program, a setback for brand-name drugmakers. The White House also expanded its TrumpRx platform by adding over 600 ge...

Ali Nemati

CybersecurityMay 1328 sec read

EU won't ban LGBTQ 'conversion therapy' but will push states to act

The European Union will not ban LGBTQ conversion therapy but will urge member states to take action against such practices. This approach reflects the EU's legal limitations and its preference for national-level legislation, impacting efforts to prot...

Ali Nemati

AI & Machine LearningMay 929 sec read

The Co-Founder Vetting System Nobody Talks About (Until It's Too Late)

A robust system for finding and evaluating co-founders emphasizes pre-screening through former colleagues, domain-specific communities, and accelerator programs rather than casual meetups or online matching apps. This approach includes rigorous crite...

Ali Nemati

Health & MedicineMay 824 sec read

Former FDA leaders, pharma speak out on mifepristone

The Supreme Court's decision on mifepristone could redefine FDA regulatory authority over abortion medications. This impacts tech professionals developing health apps and services related to reproductive health, as it may alter how digital health sol...

Ali Nemati

Biotech & PharmaMay 828 sec read

STAT+: Pharmalittle: We're reading about an FDA gender rule change, its program for one-day inspections, and more

The U.S. FDA proposed removing references to "gender" from its regulations, aiming to emphasize "biological sex," which could impact drug trials and representation of gender minorities in research. This change matters as it may alter how clinical tri...

Ali Nemati

Trump acolyte, leftist icon: Who will be Colombia's next leader?

Related Articles

STAT+: Pharmalittle: We're reading about a Supreme Court setback for pharma, TrumpRx expands and much more

EU won't ban LGBTQ 'conversion therapy' but will push states to act

The Co-Founder Vetting System Nobody Talks About (Until It's Too Late)

Former FDA leaders, pharma speak out on mifepristone

STAT+: Pharmalittle: We're reading about an FDA gender rule change, its program for one-day inspections, and more